Atezolizumab and Bevacizumab in Rare Solid Tumors
Conditions: Malignant Neoplasms of Digestive Organs; Malignant Neoplasms of Lip Oral Cavity and Pharynx; Malignant Neoplasms of Mesothelial and Soft Tissue; Malignant Neoplasms of Respiratory and Intrathoracic Organs Interventions: Drug: Atezolizumab; Drug: Bevacizumab; Behavioral: Phone Call Sponsors: M.D. Anderson Cancer Center; Genentech, Inc. Not yet recruiting - verified March 2017 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 22, 2017 Category: Research Source Type: clinical trials
Study of the Pan-ERBB Inhibitor Neratinib Given in Combination With Everolimus, Palbociclib or Trametinib in Advanced Cancer Subjects With EGFR Mutation/Amplification, HER2 Mutation/Amplification or HER3/4 Mutation
Conditions: Malignant Neoplasm of Breast; Malignant Neoplasms of Digestive Organs; Malignant Neoplasms of Female Genital Organs; Malignant Neoplasms of Ill-defined Secondary and Unspecified Sites; Malignant Neoplasms of Independent (Primary) Multiple Sites; Malignant Neoplasms of Lip Oral Cavity and Pharynx; Malignant Neoplasms of Mesothelial and Soft Tissue; Malignant Neoplasms of Respiratory and Intrathoracic Organs; Malignant Neoplasms of Thyroid and Other Endocrine Glands; Malignant Neoplasms of Urinary Tract; Neoplasms of Uncertain or Unknown Beh avior Intervention...
Source: ClinicalTrials.gov - February 22, 2017 Category: Research Source Type: clinical trials
Atezolizumab and Bevacizumab in Rare Solid Tumors
Conditions: Malignant Neoplasms of Digestive Organs; Malignant Neoplasms of Lip Oral Cavity and Pharynx; Malignant Neoplasms of Mesothelial and Soft Tissue; Malignant Neoplasms of Respiratory and Intrathoracic Organs Interventions: Drug: Atezolizumab; Drug: Bevacizumab; Behavioral: Phone Call Sponsors: M.D. Anderson Cancer Center; Genentech, Inc. Not yet recruiting - verified March 2017 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 22, 2017 Category: Research Source Type: clinical trials
Study of the Pan-ERBB Inhibitor Neratinib Given in Combination With Everolimus, Palbociclib or Trametinib in Advanced Cancer Subjects With EGFR Mutation/Amplification, HER2 Mutation/Amplification or HER3/4 Mutation
Conditions: Malignant Neoplasm of Breast; Malignant Neoplasms of Digestive Organs; Malignant Neoplasms of Female Genital Organs; Malignant Neoplasms of Ill-defined Secondary and Unspecified Sites; Malignant Neoplasms of Independent (Primary) Multiple Sites; Malignant Neoplasms of Lip Oral Cavity and Pharynx; Malignant Neoplasms of Mesothelial and Soft Tissue; Malignant Neoplasms of Respiratory and Intrathoracic Organs; Malignant Neoplasms of Thyroid and Other Endocrine Glands; Malignant Neoplasms of Urinary Tract; Neoplasms of Uncertain or Unknown Beh avior Intervention...
Source: ClinicalTrials.gov - February 22, 2017 Category: Research Source Type: clinical trials
Atezolizumab and Bevacizumab in Rare Solid Tumors
Conditions: Malignant Neoplasms of Digestive Organs; Malignant Neoplasms of Lip Oral Cavity and Pharynx; Malignant Neoplasms of Mesothelial and Soft Tissue; Malignant Neoplasms of Respiratory and Intrathoracic Organs Interventions: Drug: Atezolizumab; Drug: Bevacizumab; Behavioral: Phone Call Sponsors: M.D. Anderson Cancer Center; Genentech, Inc. Recruiting - verified March 2017 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 22, 2017 Category: Research Source Type: clinical trials
